Stockscreener 앱 받기
11.23
2.52%
-0.29
시간 외 거래:
11.54
0.31
+2.76%
전일 마감가:
$11.52
열려 있는:
$11.65
하루 거래량:
4.46M
Relative Volume:
2.48
시가총액:
$748.00M
수익:
$796.00M
순이익/손실:
$-136.49M
주가수익비율:
-5.3732
EPS:
-2.09
순현금흐름:
$-64.24M
1주 성능:
-27.08%
1개월 성능:
-32.43%
6개월 성능:
-68.89%
1년 성능:
-69.55%
1일 변동 폭
$10.77
$12.47
1주일 범위
$9.98
$15.63
52주 변동 폭
$9.98
$47.60
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
명칭
Tandem Diabetes Care Inc
전화
858-366-6900
주소
12400 HIGH BLUFF DRIVE, San Diego, CA
TNDM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
11.23 | 958.48M | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
134.28 | 227.88B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.14 | 152.55B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
377.58 | 143.34B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.88 | 114.49B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.35 | 46.11B | 5.69B | 4.14B | 577.90M | 6.96 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2025-06-16 | 개시 | Truist | Hold |
| 2025-04-10 | 개시 | Mizuho | Neutral |
| 2025-03-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-03-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | 개시 | Bernstein | Outperform |
| 2024-10-04 | 개시 | Goldman | Neutral |
| 2024-10-02 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-08-08 | 개시 | Canaccord Genuity | Buy |
| 2024-05-30 | 개시 | Redburn Atlantic | Buy |
| 2024-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-04-29 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | 업그레이드 | Stifel | Hold → Buy |
| 2023-08-04 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-05-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-04-24 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-01-26 | 개시 | Wolfe Research | Peer Perform |
| 2022-11-15 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-08-09 | 다운그레이드 | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-25 | 개시 | Barclays | Underweight |
| 2020-12-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | 개시 | Wells Fargo | Overweight |
| 2020-07-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-18 | 재확인 | Raymond James | Outperform |
| 2020-04-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-03-05 | 개시 | Citigroup | Neutral |
| 2020-02-06 | 개시 | Raymond James | Outperform |
| 2020-02-04 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | 개시 | Guggenheim | Buy |
| 2019-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2019-05-17 | 재확인 | BofA/Merrill | Neutral |
| 2019-05-13 | 개시 | SVB Leerink | Outperform |
| 2019-03-08 | 개시 | BMO Capital Markets | Outperform |
| 2019-03-05 | 재확인 | BofA/Merrill | Neutral |
| 2019-02-27 | 재확인 | Lake Street | Buy |
| 2018-11-21 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | 재확인 | Dougherty & Company | Buy |
| 2018-09-26 | 재확인 | Piper Jaffray | Overweight |
모두보기
Tandem Diabetes Care Inc 주식(TNDM)의 최신 뉴스
Tandem Diabetes projects $1B sales for 2025 as international growth, pharmacy channel, and product innovation drive outlook - MSN
Tandem Diabetes Care: Earnings Miss Confirms Bear CaseDowngrade To Sell (NASDAQ:TNDM) - Seeking Alpha
Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN
What does recent volatility data suggest for Tandem Diabetes Care Inc.Technical Analysis of Growth Stock Opportunities - Newser
Medtech Executives Monitor CMS Payment Proposal for Diabetes Technology - AInvest
How to build a custom watchlist for Tandem Diabetes Care Inc.Buy Zone Strategy with Pattern Recognition - Newser
Will Tandem Diabetes Care Inc. outperform the marketSmart Trend Analysis With Buy Point Cues - Newser
Chart based exit strategy for Tandem Diabetes Care Inc.Free Trade Ready Stock Watch for Short Term - Newser
How high can Tandem Diabetes Care Inc. stock goReal Time Screener for Growth Trades - Newser
Tandem Diabetes Care Inc. stock retracement – recovery analysisSafe Momentum Strategy With Trend Analysis - Newser
Tandem downgraded to Neutral at Piper Sandler on softer outlook - MSN
Tandem Diabetes Care Inc.’s volatility index tracking explainedWatchlist Summary for Active Day Traders - Newser
Tandem Diabetes Care issues voluntary correction for insulin pumps - Medical Buyer
Tandem Diabetes Care shares rise 4.31% intraday after UBS adjusts price target to $17. - AInvest
Tandem, Insulet monitoring CMS payment proposal for diabetes tech - MedTech Dive
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q2 2025 Earnings Call Transcript - Insider Monkey
Positive Outlook for Tandem Diabetes Care: Buy Rating Reaffirmed Amid Growth Catalysts and Strategic Opportunities - TipRanks
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say - sharewise.com
Tandem Diabetes Care’s Earnings Call Highlights Growth and Challenges - TipRanks
Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock - AOL.com
Tandem Diabetes Care Gains FDA Clearance for SteadiSet - TipRanks
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Beats Revenue Estimates - MSN
Tandem Diabetes Care (TNDM.O) Sees Sharp Intraday Decline: What’s Behind the Move? - AInvest
Tandem Diabetes Care issues voluntary device correction for certain insulin pumps - Reuters
Tandem insulin pump malfunction linked to 59 injuries - MedTech Dive
Tandem Diabetes' Stalled Momentum: Is the Market Overestimating Long-Term Resilience? - AInvest
TNDM.O Crashes 24.5%: What’s Behind the Sharp Drop? - AInvest
Tandem Diabetes Care price target lowered to $20 at TD Cowen on US sales concerns - Investing.com Canada
Tandem Diabetes announces medical device correction for t:slim X2 insulin pumps - TipRanks
TNDM.O Plummets 25%—What’s Behind the Sharp Move? - AInvest
UBS Adjusts Price Target on Tandem Diabetes Care to $17 From $20, Maintains Neutral Rating - MarketScreener
Earnings call transcript: Tandem Diabetes Care Q2 2025 misses EPS expectations - Investing.com Nigeria
Tandem Diabetes Care hits 7-year low on issuing voluntary device correction for certain insulin pumps - TradingView
Tandem Diabetes Plunges 21.2%: Can a Speaker Glitch Spell the End of a Diabetes Tech Giant? - AInvest
Truist Cuts Price Target on Tandem Diabetes Care to $14 From $15, Keeps Hold Rating - MarketScreener
Tandem Diabetes Issues Correction for Certain t:slim X2 Insulin Pumps - Medical Product Outsourcing
Tandem Diabetes Care drops after issuing voluntary device correction for certain insulin pumps - TradingView
Tandem Diabetes price target lowered to $13 from $20 at Wells Fargo - TipRanks
Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps | TNDM Stock News - GuruFocus
Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps - Yahoo Finance
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Tandem Diabetes shares fall 18.97% premarket after Q2 sales miss expectations. - AInvest
Tandem Diabetes Care Q2 2025: Revenue Surges but Profitability Concerns PersistNews and Statistics - IndexBox
Tandem Diabetes downgraded to Neutral from Overweight at Piper Sandler - TipRanks
Tandem Diabetes Care Hits Sales Milestone But Stays In The Red - Finimize
Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance - ADVFN Brasil
Earnings call transcript: Tandem Diabetes Care Q2 2025 misses EPS expectations By Investing.com - Investing.com South Africa
Piper Sandler downgrades Tandem Diabetes stock on weak domestic outlook By Investing.com - Investing.com Canada
Transcript : Tandem Diabetes Care, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Tandem Diabetes Care Reports Record Q2 2025 Sales - TipRanks
Tandem Diabetes Care 2025 Q2 Earnings Worse Losses Amid Revenue Growth - AInvest
Tandem Diabetes Care Inc (TNDM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
자본화:
|
볼륨(24시간):